Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.

Biomaterials - 1 Oct 2015

Gao Dong-Yu, Lin Ts-Ting, Sung Yun-Chieh, Liu Ya Chi, Chiang Wen-Hsuan, Chang Chih-Chun, Liu Jia-Yu, Chen Yunching

Abstract excerpt

Sorafenib, a multikinase inhibitor, has been used as an anti-angiogenic agent against highly vascular hepatocellular carcinoma (HCC) - yet associated with only moderate therapeutic effect and the high incidence of HCC recurrence. We have shown intratumoral hypoxia induced by sorafenib activated C-X-C receptor type 4 (CXCR4)/stromal-derived factor 1α (SDF1α) axis, resulting in polarization toward a tumor-promoting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Delivery Systems
Share to Human Umbilical Vein Endothelial Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lactic Acid

Share to Nanoparticles

Share to Niacinamide

Share to Phenylurea Compounds

Share to Receptors, CXCR4

Share to Sorafenib

Source

Identifiers

PMID: 26218745
DOI: 10.1016/j.biomaterials.2015.07.035

Genes

CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.PMID 26218745Read ↗

Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver CancerSemantic proximity Read ↗

Engineered Exosomes for the Targeted Delivery of A Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma.Semantic proximity Read ↗

Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinomaSemantic proximity Read ↗

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1αSemantic proximity Read ↗

Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.Semantic proximity Read ↗

Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts.Semantic proximity Read ↗

Remodeling tumor microenvironment by liposomal co-delivery of DMXAA and simvastatin inhibits malignant melanoma progressionSemantic proximity Read ↗

PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cellsSemantic proximity Read ↗

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCCSemantic proximity Read ↗

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.Semantic proximity Read ↗

Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

ALPPL2‐Binding Peptide Facilitates Targeted mRNA Delivery for Efficient Hepatocellular Carcinoma Gene TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.